Cited by 204Genetic Neurodegenerative DiseasesCurcumin's Biomedical ApplicationsParkinson's Disease Mechanisms and Treatments

Curcumin nanoparticles attenuate neurochemical and neurobehavioral deficits in experimental model of huntington’s disease.

Sandhir, Rajat, Yadav, Aarti, Mehrotra, Arpit, Sunkaria, Aditya, Singh, Amandeep, Sharma, Sadhna·2014·NeuroMolecular Medicine

Abstract

Till date, an exact causative pathway responsible for neurodegeneration in Huntington's disease (HD) remains elusive; however, mitochondrial dysfunction appears to play an important role in HD pathogenesis. Therefore, strategies to attenuate mitochondrial impairments could provide a potential therapeutic intervention. In the present study, we used curcumin encapsulated solid lipid nanoparticles (C-SLNs) to ameliorate 3-nitropropionic acid (3-NP)-induced HD in rats. Results of MTT (3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide) assay and succinate dehydrogenase (SDH) staining of striatum revealed a marked decrease in Complex II activity. However, C-SLN-treated animals showed significant increase in the activity of mitochondrial complexes and cytochrome levels. C-SLNs also restored the glutathione levels and superoxide dismutase activity. Moreover, significant reduction in mitochondrial swelling, lipid peroxidation, protein carbonyls and reactive oxygen species was observed in rats treated with C-SLNs. Quantitative PCR and Western blot results revealed the activation of nuclear factor-erythroid 2 antioxidant pathway after C-SLNs administration in 3-NP-treated animals. In addition, C-SLN-treated rats showed significant improvement in neuromotor coordination when compared with 3-NP-treated rats. Thus, the results of this study suggest that C-SLNs administration might be a promising therapeutic intervention to ameliorate mitochondrial dysfunctions in HD.

Integrity signals

Registry

Crossref · 10.1007/s12017-013-8261-y

Cites

72 of 72 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Solid-lipid-based curcumin nanoformulation attenuates 3-nitropropionic-acid-induced Huntington's disease in rats by increasing complex II activity and restoring glutathione and superoxide dismutase.

    “Attenuated 3-nitropropionic-acid- induced Huntington’s disease in rats by increasing complex II activity, restoring the glutathione and superoxide dismutase”

    From Nanotechnology: A Promising Approach for Delivery of Neuroprotective Drugs (2020) · cites this paper as Sandhir et al., 2014

Cites

1 retracted

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Sandhir, R., Yadav, A., Mehrotra, A., Sunkaria, A., Singh, A., & Sharma, S.
Affiliations
  • Panjab University (IN)
  • Post Graduate Institute of Medical Education and Research (IN)
Corresponding author
Sandhir, Rajat
Venue
NeuroMolecular Medicine
Published
2013-09-06
Volume
16
Issue
1
Pages
106-118
ISSN
  • 1535-1084 (ISSN-L)
  • 1559-1174
OpenAlex
W1992478997
Cited by
204
References
72
Citations by year
2026: 12 · 2025: 19 · 2024: 23 · 2023: 28 · 2022: 29 · 2021: 14 · 2020: 19 · 2019: 20 · 2018: 9 · 2017: 9 · 2016: 2 · 2015: 12 · 2014: 8
FWCI
3.60
Type
journal article
Language
en
Open access
closed
Locations
  • NeuroMolecular Medicine (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Department of Science and Technology, Ministry of Science and Technology, India
  • University Grants Commission
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Genetic Neurodegenerative Diseases
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Medicine › Curcumin's Biomedical Applications
  • Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
Keywords
curcumin, solid lipid nanoparticles, Huntington's disease, 3-nitropropionic acid, mitochondrial dysfunction, neuroprotection, oxidative stress, glutathione, superoxide dismutase, lipid peroxidation, protein carbonylation, succinate dehydrogenase, striatum, neurobehavioral deficits
MeSH terms
Animals, Ataxia, Corpus Striatum, Curcumin, Disease Models, Animal, Drug Evaluation, Preclinical, Female, Glutathione, Humans, Huntington Disease, Lameness, Animal, Phytotherapy, Mitochondria, Motor Activity, Nitro Compounds, Propionates, Random Allocation, Superoxide Dismutase, Lipid Peroxidation, Rats, Wistar, Reactive Oxygen Species, Oxidative Stress, NF-E2-Related Factor 2, Rats, Nanoparticles

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review